Result of general meeting

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Result of general meeting

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed. 

As a result, the Placing announced on 14 March 2014 of 5,263,158 new ordinary shares at 19p per ordinary share, is conditional only on Admission which is expected to take place on 2 April 2014.

The Directors intend to use the net proceeds of the Placing to develop the opportunities provided by the recent acquisition of Labskin™ and the SYN1113 intellectual property rights.

Following Admission, the Company's issued share capital will consist of 28,190,441 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that following Admission, the total number of voting rights in the Company will be 28,190,441.

Enquiries:

Venn Life Sciences Holdings Plc

Tony Richardson, Chief Executive Officer Tel: +353 154 99 341

Paul Foulger, Finance Director Tel: 020 7933 8797

Orla McGuinness, Marketing Manager Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance) Tel: 0161 831 1512

John Goold/ Alex Davies/ Dominic Wilson (institutional Sales) Tel: 0207 533 7727

Walbrook PR Ltd Tel: 020 7933 8787

[email protected]

Paul McManus Mob: 07980 541 893

Lianne Cawthorne Mob: 07584 391 303

Additional Information:

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Germany, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The company's near term objectives are the expansion of its CRO business throughout Europe, whilst enhancing the portfolio of their innovative technologies division, InnoVenn, with ground breaking new products and services.